Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

A collection of top researchers have made the case for a new way to understand and diagnose obesity beyond using BMI as a measure.

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

US pharma major Eli Lilly’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.